|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1994 (US)
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50-60%
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
metabolic acidosis
renal impairment
acute or chronic metabolic acidosis
|
|
gptkbp:eliminationHalfLife
|
4-8.7 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
oral solution
|
|
gptkbp:hasChEMBL
|
gptkb:CHEMBL1431
|
|
gptkbp:hasDrugBankURL
|
https://go.drugbank.com/drugs/DB00713
|
|
gptkbp:hasInChIKey
|
gptkb:XZWYZXLIPXDOLR-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C4H11N5
|
|
gptkbp:hasSMILES
|
CN(C)C(=N)N=C(N)N
|
|
gptkbp:hasUNII
|
9100L32L2N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB00713
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
gptkb:polycystic_ovary_syndrome_(off-label)
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
decreases hepatic glucose production
increases insulin sensitivity
decreases intestinal absorption of glucose
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:molecularWeight
|
129.164
|
|
gptkbp:name
|
gptkb:Metformin
|
|
gptkbp:originatedIn
|
synthetic
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
negligible
|
|
gptkbp:PubChem_CID
|
6801
4091
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
gastrointestinal upset
lactic acidosis
|
|
gptkbp:synonym
|
1,1-dimethylbiguanide
dimethylbiguanide
|
|
gptkbp:target
|
gptkb:AMP-activated_protein_kinase
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:oxacillin
|
|
gptkbp:bfsLayer
|
7
|